# Celularity Inc: overview CELU · Nasdaq · CIK 1752828 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/celu.md) · [Financials](/companies/celu/financials.md) · [Filings](/companies/celu/filings.md) · [Insiders](/companies/celu/insiders.md) Latest reported revenue: [$5.4m](/filings/0001493152-26-047787.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Oct 20, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-047787). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [9.3](/filings/0001493152-25-023467.md) | [18.1 d](/filings/0001493152-26-020424.md) | [11.4](/filings/0001493152-26-044892.md) | [5.7](/filings/0001493152-26-047787.md) | [5.3](/filings/0001493152-25-023467.md) | [4.1 d](/filings/0001493152-26-020424.md) | [3.8](/filings/0001493152-26-044892.md) | [5.4](/filings/0001493152-26-047787.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(124.0%)](/filings/0001493152-25-023467.md) | [(51.2%) d](/filings/0001493152-26-020424.md) | [(91.8%)](/filings/0001493152-26-044892.md) | [(276.6%)](/filings/0001493152-26-047787.md) | [(244.1%)](/filings/0001493152-25-023467.md) | [(537.5%) d](/filings/0001493152-26-020424.md) | [(263.5%)](/filings/0001493152-26-044892.md) | [(78.0%)](/filings/0001493152-26-047787.md) | | Net margin | % | [(173.2%)](/filings/0001493152-25-023467.md) | [(73.3%) d](/filings/0001493152-26-020424.md) | [(172.9%)](/filings/0001493152-26-047787.md) | [(427.5%)](/filings/0001493152-26-047787.md) | [(436.7%)](/filings/0001493152-25-023467.md) | [(593.6%) d](/filings/0001493152-26-020424.md) | [22.7%](/filings/0001493152-26-047787.md) | [13.0%](/filings/0001493152-26-047787.md) | | Diluted EPS | $ per share | [(0.73)](/filings/0001493152-25-023467.md) | not reported | [(0.84)](/filings/0001493152-26-044892.md) | [(1.02)](/filings/0001493152-26-047787.md) | [(0.88)](/filings/0001493152-25-023467.md) | not reported | [0.02](/filings/0001493152-26-044892.md) | [0.02](/filings/0001493152-26-047787.md) | | Free cash flow | $m | [(0.1) d](/filings/0001493152-25-023467.md) | [1.5 d](/filings/0001493152-26-020424.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.3](/filings/0000950170-23-011440.md) | [18.0](/filings/0000950170-24-087886.md) | [22.8](/filings/0001641172-25-009319.md) | [54.2](/filings/0001493152-26-020424.md) | [26.6](/filings/0001493152-26-020424.md) | | Gross margin | % | [54.8%](/filings/0000950170-23-011440.md) | [(9.4%)](/filings/0000950170-24-087886.md) | [29.7%](/filings/0000950170-24-087886.md) | not reported | not reported | | Operating margin | % | [(511.2%)](/filings/0000950170-23-011440.md) | [(142.4%)](/filings/0000950170-24-087886.md) | [(844.4%)](/filings/0001641172-25-009319.md) | [(70.7%)](/filings/0001493152-26-020424.md) | [(230.9%)](/filings/0001493152-26-020424.md) | | Net margin | % | [(469.3%)](/filings/0000950170-23-011440.md) | [79.0%](/filings/0000950170-24-087886.md) | [(862.0%)](/filings/0001641172-25-009319.md) | [(106.8%)](/filings/0001493152-26-020424.md) | [(345.4%)](/filings/0001493152-26-020424.md) | | Diluted EPS | $ per share | [(1.49)](/filings/0000950170-23-011440.md) | [0.95](/filings/0000950170-24-087886.md) | [(11.02)](/filings/0001641172-25-009319.md) | [(2.64)](/filings/0001493152-26-020424.md) | [(3.59)](/filings/0001493152-26-020424.md) | | Free cash flow | $m | [(116)](/filings/0000950170-23-011440.md) | [(143)](/filings/0000950170-24-087886.md) | [(39.7)](/filings/0001641172-25-009319.md) | [(6.6)](/filings/0001493152-26-020424.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/celu/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [C V STARR & CO INC](/funds/1340459.md) | 2026-06-30 | $1.6m | 764,069 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $371.4k | 621,105 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $100.0k | 167,150 | | Reduced −23,926 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $59.2k | 99,054 | | New +99,054 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $47.8k | 79,874 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $45.7k | 76,359 | | Reduced −51,142 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $34.6k | 57,830 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $26.4k | 44,163 | | Unchanged | | [Biltmore Family Office, LLC](/funds/1731123.md) | 2026-06-30 | $20.9k | 35,000 | | Unchanged | | [HB Wealth Management, LLC](/funds/1911253.md) | 2026-06-30 | $19.1k | 31,915 | | Reduced −8,500 | ## Recent filings [All 554 filings](/companies/celu/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 17:08 ET | [10-Q](/filings/0001493152-26-047787.md) | Quarterly report, period 2026-06-30 | 0001493152-26-047787 | | 2026-10-20 | 09:15 ET | [10-K/A](/filings/0001493152-26-047708.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-047708 | | 2026-09-29 | 17:25 ET | [8-K](/filings/0001493152-26-044917.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-044917 | | 2026-09-29 | 17:02 ET | [10-Q](/filings/0001493152-26-044892.md) | Quarterly report, period 2026-03-31 | 0001493152-26-044892 | | 2026-09-28 | 13:14 ET | [SCHEDULE 13D/A](/filings/0001104659-26-111279.md) | Ownership report, active investor, amended | 0001104659-26-111279 | | 2026-09-28 | 06:14 ET | [8-K](/filings/0001493152-26-044421.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-044421 | | 2026-09-14 | 09:00 ET | [8-K](/filings/0001493152-26-042495.md) | 8.01 Other events | 0001493152-26-042495 | | 2026-08-07 | 17:10 ET | [8-K](/filings/0001493152-26-036648.md) | 5.02 Departure or appointment of officers or directors | 0001493152-26-036648 | | 2026-07-29 | 16:15 ET | [8-K](/filings/0001493152-26-035193.md) | 3.01 Delisting notice | 0001493152-26-035193 | | 2026-06-30 | 09:00 ET | [8-K](/filings/0001493152-26-031216.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-031216 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-020424.md), filed Apr 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1752828 - Tickers: CELU - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 09:26 ET. No prices; not investment advice.